🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are increasing globally, with figures suggesting more than 82 million instances per year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, escalating drug resistance and the extremely scarce available drugs at this time.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The global health body has listed it as a "critical concern". A tracking program showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in mid-December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization represents a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Data and Global Access

As per data released by a major medical journal, zoliflodacin eradicated the vast majority of uncomplicated infections. This puts it on an equal footing with the current standard treatment, which combines an injection and a pill. The trial involved hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to license and sell the drug in numerous developing nations.

Medical professionals on the front lines have voiced hope. The availability of a single-dose, oral treatment such as this is seen as a "game-changer" for gonorrhoea control. This is considered essential to lessen the impact of the disease for patients and to prevent the spread of untreatable gonorrhoea globally.